相关实验视频

Updated: Sep 16, 2025

Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

1.3K

轻度至中度阿尔茨海默病患者的低剂量互白素-2:一项随机临床试验

Alireza Faridar1,2, Nazaret Gamez3, Daling Li3

  • 1Stanley H. Appel Department of Neurology, Houston Methodist Research Institute, Houston, TX, 77030, USA. afaridar@houstonmethodist.org.

Alzheimer's research & therapy
|July 4, 2025
PubMed
概括

对阿尔茨海默氏病 (AD) 患者来说,低剂量介素-2 (IL-2) 治疗是安全的. 每4周一次的剂量方案扩大了调节性T细胞 (Tregs),改善了生物标志物,并显示出减缓疾病进展的潜力.

关键词:
阿尔茨海默氏症是阿尔茨海默氏症的疾病.临床试验临床试验是指临床试验的临床试验.免疫系统的免疫系统.免疫治疗是一种免疫疗法.炎症 炎症是一种炎症.这就是Treg Treg.

更多相关视频

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

42.9K
A Protocol for Transcranial Photobiomodulation Therapy in Mice13:07

A Protocol for Transcranial Photobiomodulation Therapy in Mice

Published on: November 18, 2018

12.3K

相关概念视频

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
675
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
389
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
275
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K